Recently, we have received the Supplementary Drug Application Approval from the NMPA for Amoxicillin - Amoxicillin Capsules (0.25 g, 0.5 g) and Greats® - Irbesartan Tablets (75 mg). The products have passed the generic drug consistency evaluation, indicating that they have reached the level of consistency with the original drug in terms of quality and efficacy.

 Adhering to the corporate philosophy of “Tech C&O  Persistent improving”, we are committed to creating high-quality generic drugs and contributing to the improvement of national health.